Rian Hollister: PlasmaFlow As An Option for Continued DVT Prevention
Rian Hollister, Territory Manager at Recon Supply, shared on LinkedIn:
”To all my fellow veterans, ask your VA providers/staff about PlasmaFlow as an option for continued DVT prevention from hospital/medical facility to home.
‘U.S. Centers for Medicare and Medicaid Services (CMS) declared deep vein thrombosis (DVT) a Never Event in 2008, yet it remains the leading cause of preventable death in hospitalized patients each year.’
‘The PlasmaFlow™ Portable Compression Device can reduce DVT risk by providing hospital-quality vascular compression therapy to patients wherever they recover.
DVT risk doesn’t end when a patient is discharged.
With more high-risk surgeries moving from inpatient to outpatient settings, effective compression therapy after discharge is critical.
CHEST guidelines recommend extending thromboprophylaxis in the outpatient period for up to 35 days from the day of surgery for patients undergoing major orthopedic surgery.’
- 60% of HA-VTEs occur after patients have been discharged.
- As many as 70% of HA-VTE cases in patients could be prevented.
“Healthcare-associated venous thromboembolism (HA-VTE) leads to approximately 100,000 premature deaths annually.”
Mean time to presentation for symptomatic DVT:
Total Knee Arthroplasty (TKA) patients = 19.5 days
Total Hip Arthroplasty (THA) patients = 22.5 days
‘The PlasmaFlow™ Portable Compression Device provides continuous DVT prevention for patients returning home to recover.
This portable compression device is comfortable and convenient, ensuring better protection for patients and peace of mind for providers.”’
Stay updated with Hemostasis Today.
-
Jul 13, 2026, 17:39Pascal Boulanger: Send a Postcard to Your Lab Staff From ISTH 2026
-
Jul 13, 2026, 17:21Stefano Navarro: Presenting Our Recently Published Article at ISTH 2026
-
Jul 13, 2026, 17:12Santagata Davide: A Great Session and an Incredible Opportunity to Present Our Research at ISTH 2026
-
Jul 13, 2026, 16:26Real-World Data Across Time Reveal Important Advances in Hemophilia Treatment – ATHN
-
Jul 13, 2026, 16:19Mary Cushman: Celebrating Our Incredible ISTH Council Members in Paris
-
Jul 13, 2026, 16:17Wolfgang Miesbach: Gene Therapy Shows Promising Early Results in Adolescents With Hemophilia B at ISTH 2026
-
Jul 13, 2026, 16:06Dino Mehic: Honored to Receive the ISTH Early Career Top Reviewer Awards
-
Jul 13, 2026, 16:01Advancing DIC Diagnosis in Cirrhosis Through Disease-Specific Risk Stratification – JTH
-
Jul 13, 2026, 15:52Joshua Muia: Presenting Our Research on ADAMTS13/VWF Dysregulation in Sepsis at ISTH 2026